Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIT-00814 in advanced solid tumors
NCT06205082Phase 1Enrolling by invitation
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LIT-00814 in solid tumor (advanced stage) and esophageal cancer (4 arms), sponsored by Jiangsu Nutai Biologics Co., Ltd. Primary endpoints: Incidence of adverse events and Determination of the MTD and RP2D of LIT-00814 monotherapy. Started Oct 2023; status: enrolling by invitation.
02
Drugs
LIT-00814
03
Conditions
solid tumor (advanced stage)esophageal cancer
Beyond the preview
Go deeper on NCT06205082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205082.